Go Pro
→ Trump Takes Emergency Action - Plus Elon Musk's New Venture (From Altimetry) (Ad)tc pixel Free KTTAW Stock Alerts

Pasithea Therapeutics (KTTAW) Competitors

$0.0069 0.00 (-1.43%)
Closing price 08/14/2026 07:57 AM Eastern
Extended Trading
$0.01 0.00 (0.00%)
As of 08/14/2026 07:57 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

KTTAW vs. ALVOW, APLMW, ARAV, BIAFW, and BIVIW

Should you buy Pasithea Therapeutics stock or one of its competitors? Pasithea Therapeutics's main competitors and comparable companies include Alvotech (ALVOW), Apollomics (APLMW), Aravive (ARAV), bioAffinity Technologies (BIAFW), and BioVie (BIVIW). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Pasithea Therapeutics compare to Alvotech?

Alvotech (NASDAQ:ALVOW) and Pasithea Therapeutics (NASDAQ:KTTAW) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, dividends, risk, profitability, earnings and media sentiment.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alvotech$559.42MN/AN/AN/AN/A
Pasithea TherapeuticsN/AN/AN/AN/AN/A

In the previous week, Alvotech and Alvotech both had 1 articles in the media. Pasithea Therapeutics' average media sentiment score of 1.89 beat Alvotech's score of 0.93 indicating that Pasithea Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Alvotech Positive
Pasithea Therapeutics Very Positive

Company Net Margins Return on Equity Return on Assets
AlvotechN/A N/A N/A
Pasithea Therapeutics N/A N/A N/A

Summary

Alvotech and Pasithea Therapeutics tied by winning 1 of the 2 factors compared between the two stocks.

How does Pasithea Therapeutics compare to Apollomics?

Apollomics (NASDAQ:APLMW) and Pasithea Therapeutics (NASDAQ:KTTAW) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, risk, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.

In the previous week, Apollomics had 2 more articles in the media than Pasithea Therapeutics. MarketBeat recorded 3 mentions for Apollomics and 1 mentions for Pasithea Therapeutics. Pasithea Therapeutics' average media sentiment score of 1.89 beat Apollomics' score of 0.29 indicating that Pasithea Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Apollomics Neutral
Pasithea Therapeutics Very Positive

Company Net Margins Return on Equity Return on Assets
ApollomicsN/A N/A N/A
Pasithea Therapeutics N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Apollomics$8.50MN/AN/AN/AN/A
Pasithea TherapeuticsN/AN/AN/AN/AN/A

Summary

Apollomics beats Pasithea Therapeutics on 2 of the 3 factors compared between the two stocks.

How does Pasithea Therapeutics compare to Aravive?

Aravive (NASDAQ:ARAV) and Pasithea Therapeutics (NASDAQ:KTTAW) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, dividends, risk, earnings, analyst recommendations, valuation, media sentiment and institutional ownership.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AraviveN/AN/AN/A-$0.90N/A
Pasithea TherapeuticsN/AN/AN/AN/AN/A

In the previous week, Pasithea Therapeutics had 1 more articles in the media than Aravive. MarketBeat recorded 1 mentions for Pasithea Therapeutics and 0 mentions for Aravive. Pasithea Therapeutics' average media sentiment score of 1.89 beat Aravive's score of 0.00 indicating that Pasithea Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Aravive Neutral
Pasithea Therapeutics Very Positive

Company Net Margins Return on Equity Return on Assets
AraviveN/A N/A N/A
Pasithea Therapeutics N/A N/A N/A

35.8% of Aravive shares are held by institutional investors. 60.4% of Aravive shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Aravive and Pasithea Therapeutics tied by winning 2 of the 4 factors compared between the two stocks.

How does Pasithea Therapeutics compare to bioAffinity Technologies?

bioAffinity Technologies (NASDAQ:BIAFW) and Pasithea Therapeutics (NASDAQ:KTTAW) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, media sentiment, profitability, institutional ownership, earnings and valuation.

Company Net Margins Return on Equity Return on Assets
bioAffinity TechnologiesN/A N/A N/A
Pasithea Therapeutics N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
bioAffinity Technologies$5.85MN/AN/AN/AN/A
Pasithea TherapeuticsN/AN/AN/AN/AN/A

In the previous week, bioAffinity Technologies had 1 more articles in the media than Pasithea Therapeutics. MarketBeat recorded 2 mentions for bioAffinity Technologies and 1 mentions for Pasithea Therapeutics. Pasithea Therapeutics' average media sentiment score of 1.89 beat bioAffinity Technologies' score of 0.63 indicating that Pasithea Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
bioAffinity Technologies Positive
Pasithea Therapeutics Very Positive

Summary

bioAffinity Technologies beats Pasithea Therapeutics on 2 of the 3 factors compared between the two stocks.

How does Pasithea Therapeutics compare to BioVie?

Pasithea Therapeutics (NASDAQ:KTTAW) and BioVie (NASDAQ:BIVIW) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, media sentiment, analyst recommendations, risk, profitability and earnings.

In the previous week, BioVie had 1 more articles in the media than Pasithea Therapeutics. MarketBeat recorded 2 mentions for BioVie and 1 mentions for Pasithea Therapeutics. Pasithea Therapeutics' average media sentiment score of 1.89 beat BioVie's score of 0.82 indicating that Pasithea Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Pasithea Therapeutics Very Positive
BioVie Positive

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pasithea TherapeuticsN/AN/AN/AN/AN/A
BioVieN/AN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
Pasithea TherapeuticsN/A N/A N/A
BioVie N/A N/A N/A

Summary

Pasithea Therapeutics and BioVie tied by winning 1 of the 2 factors compared between the two stocks.

Get Pasithea Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for KTTAW and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KTTAW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

KTTAW vs. The Competition

Export
MetricPasithea TherapeuticsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market CapN/A$3.74B$7.03B$13.06B
Dividend YieldN/A3.69%2.56%10.62%
P/E RatioN/A11.49270.8525.39
Price / SalesN/A1,303.47607.8392.50
Price / CashN/A45.1128.8738.47
Price / BookN/A17.1711.096.51
Net IncomeN/A-$13.18M$3.45B$347.22M
7 Day PerformanceN/A1.53%0.74%1.51%
1 Month PerformanceN/A2.99%2.15%2.74%
1 Year PerformanceN/A56.69%63.00%21.07%

Pasithea Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
KTTAW
Pasithea Therapeutics
N/A$0.01
-1.4%		N/A-55.5%$0.00N/AN/A3
ALVOW
Alvotech
N/A$0.15
flat		N/A-83.5%$0.00$559.42MN/A4
APLMW
Apollomics
N/A$0.02
flat		N/A-19.3%$0.00$8.50MN/A59
ARAV
Aravive
N/A$0.04
flat		N/AN/A$0.00N/AN/A20
BIAFW
bioAffinity Technologies
N/A$0.07
+16.7%		N/AN/A$0.00$5.61MN/A10

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:KTTAW) was last updated on 8/17/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel